MBRX is trading 6.7% down at $2.51 today, as investor sentiment continues to be impacted by recent interim clinical trial data. - On June 30, 2026, Moleculin Biotech announced interim data from its Annamycin trial in AML did not achieve statistical significance, causing shares to plunge over 25%. - The independent safety board reviewing the study noted a clear trend favoring the Annamycin combination but recommended continuing the trial to determine the best dose. - Full data from the first part of the trial is expected in the second half of 2026, leaving investors awaiting further clarity on the drug's efficacy.